Treatment of APAP Toxicity With IV and Oral NAC 2008-2011

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

47 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-06-30

Study Completion Date

2011-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Retrospective chart review of patients who receive N-acetylcysteine for Acetaminophen(APAP) toxicity to assess length of oral vs. IV treatment and the effect of a Clinical Pharmacology and Toxicology division in the management of APAP ingestions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Plasma Exchange for Amanita Toxin-induced Acute Liver Failure

NCT06187220

Acute Liver Failure

COMPLETED

Randomized Study of Succimer (Dimercaptosuccinic Acid) on Growth of Lead-Poisoned Children

NCT00004838

Lead Poisoning

COMPLETED NA

Risk Stratification and Heterogeneity for Organ Damage in Acute Diquat Poisoning

NCT06798142

Toxic Encephalopathy Diquat Poisoning

ACTIVE_NOT_RECRUITING

Leveraging Plasma Concentration Levels to Optimize Extracorporeal Treatment in Acute Diquat Poisoning

NCT06807151

Diquat Poisoning Blood Purification

COMPLETED

Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department

NCT00657228

Anaphylaxis

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acetaminophen Toxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral NAC

Patients receiving oral NAC treatment after an acute acetaminophen ingestion.

No interventions assigned to this group

IV NAC

Patients receiving IV NAC after an acute Acetaminophen ingestion.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Admitted to CHMCA between June 1, 2008 to June 30, 2011
* Qualifying ICD-9 diagnosis code for the following APAP overdose situations: poisoning, accidental, suicide attempt, therapeutic use, assault, and undetermined (965.4, E850.4, E950.0, E935.4, E962.0, E980.0)
* Serum APAP concentration above the possible hepatotoxic line on the Rumack-Matthew's nomogram if obtained \> 4 hours post ingestion
* Between ages 0-21 years on date of admission
* Acute APAP ingestion

Exclusion Criteria

* Serum APAP concentrations not actually documented
* Did not receive the oral or IV NAC treatment
* Preexisting liver disease such as cirrhosis or hepatitis C
* Patient \> 21 years of age on the date of admission
* Chronic APAP ingestion

Minimum Eligible Age

1 Month

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No